Comparison of MENOPUR Liquid and Powder in Women Undergoing ART

• Status: Completed
• Trial end date: 2021-07-16
• Target enrollment: 0
• Participant gender: Female

Summary

Development of multiple follicles and pregnancy in ovulatory women undergoing controlled ovarian stimulation as part of an assisted reproductive technology (ART) cycle.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals
• Treatments: Menotropins; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Signed informed consents, prior to any trial-related procedure.

• Females between the ages of 18 and 42 years. The participants must be at least 18 years (including the 18th birthday) when they sign the informed consent and no more than 42 years (up to the day before the 43rd birthday) at the time of randomization who desire pregnancy.

• Body mass index (BMI) between 17.5 and 38.0 kg/m^2 (both inclusive) at screening.

• Regular menstrual cycles of 24 to 35 days, presumed to be ovulatory.

• Documented history of infertility for at least 12 months before randomization for women ≤35 years or for at least 6 months for women ≥36 years. Women with documented bilateral tubal occlusion or male factor infertility requiring the use of donor sperm established as a cause of infertility are eligible at diagnosis.

• Early follicular phase (cycle day 2-4) serum FSH level between 1 and 12 IU/L (results obtained within 3 months prior to randomization).

• Male partner with semen analysis that is at least adequate for intracytoplasmic sperm injection (ICSI) at screening or within 6 months prior to the screening date. Partners with severe male factors requiring invasive or surgical sperm retrieval may not be used. Use of donor sperm is allowed.

• At least 1 cycle with no fertility medication immediately prior to screening.

• Hysterosalpingography, hysteroscopy, or saline hysterosonogram documenting uterine anatomy appropriate for ART at screening or within 12 months prior to screening.

• Transvaginal ultrasound documenting presence and adequate visualization of both ovaries, without evidence of clinically significant abnormality (e.g., endometrioma ≥3 cm, no dermoid cysts) and normal adnexa (e.g., no hydrosalpinx) at screening. Both ovaries must be accessible for oocyte retrieval.

Exclusion Criteria:

• More than two previous controlled ovarian stimulation cycles for in vitro fertilization (IVF)/ICSI

• Known stage III-IV endometriosis (American Society for Reproductive Medicine, 2012).

• Oocyte donor or embryo recipient; gestational or surrogate carrier.

• Known history of recurrent miscarriage (defined as three consecutive losses after ultrasound confirmation of pregnancy [excluding ectopic pregnancy] and before week 24 of pregnancy).

• Participant's male partner, with obvious leukospermia (>2 million white blood cells/mL) or signs of infection in semen sample within 6 months of the participant's screening. If either of these conditions exists, the male should be treated with antibiotics and retested prior to the participant's randomization.

• Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.

• Any known endocrine (total testosterone, prolactin and TSH) or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) with the exception of controlled thyroid function disease.

• Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus which would contraindicate the use of gonadotrophins.

• Any abnormal finding of clinical chemistry, hematology and vital signs at screening, which is judged clinically significant by the investigator.

• Pregnancy (negative urine pregnancy test must be documented at screening and prior to the first investigational medicinal product [IMP] administration), or contraindication to pregnancy.

• Hypersensitivity to any active ingredient or excipients in the medicinal products used in this trial.